[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570847":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":100,"collaborators":102,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":10,"enrollmentInfo":115,"targetDuration":10,"studyType":118,"phases":10,"briefSummary":119,"conditions":120,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BGF Initiators",null,"New initiators of BGF without prior BGF exposure",[13],"Drug: Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate","Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist",[9],[21],"BGF, Breztri",[23],{"name":24,"affiliation":5,"role":25},"Michael F Pollack, MS","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[33,45,55,64,73,82,91],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Research Site","NOT_YET_RECRUITING","Mississauga","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-79.6583,43.5789,{"lat":43,"lon":42},{"facility":34,"status":46,"city":47,"state":10,"zip":10,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":10},"RECRUITING","Hamburg","Germany","DE",{"type":40,"coordinates":51},[52,53],9.99302,53.55073,{"lat":53,"lon":52},{"facility":34,"status":46,"city":56,"state":10,"zip":10,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"Athens","Greece","GR",{"type":40,"coordinates":60},[61,62],23.72784,37.98376,{"lat":62,"lon":61},{"facility":34,"status":46,"city":65,"state":10,"zip":10,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"Milan","Italy","IT",{"type":40,"coordinates":69},[70,71],9.18951,45.46427,{"lat":71,"lon":70},{"facility":34,"status":46,"city":74,"state":10,"zip":10,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":10},"Tokyo","Japan","JP",{"type":40,"coordinates":78},[79,80],139.69171,35.6895,{"lat":80,"lon":79},{"facility":34,"status":35,"city":83,"state":10,"zip":10,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":10},"Bucharest","Romania","RO",{"type":40,"coordinates":87},[88,89],26.10626,44.43225,{"lat":89,"lon":88},{"facility":34,"status":46,"city":92,"state":10,"zip":10,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":10},"London","United Kingdom","UK",{"type":40,"coordinates":96},[97,98],-0.12574,51.50853,{"lat":98,"lon":97},{"type":101,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[103],{"name":104,"class":6},"IQVIA Pty Ltd","100570847","pooled-analysis-of-single-arm-studies-of-budesonideglycopyrroniumformoterol-bgf-in-routine-care-setting-100570847",false,"NCT06712563","Pooled Analysis of Single-arm Studies of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","Pooled Analysis of Multi-country, Open-label Single-arm, Non-interventional, Multi-center, Cohort Studies of Real-world Outcomes in New Users of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","CHOROS","Inclusion Criteria:\n\n* Patients with moderate to severe COPD and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation\n* Enrolled in on-going single-arm studies\n* Provided consent for secondary use of data\n\nExclusion Criteria:\n\n* Did not provide consent for secondary use of data","ALL","18 Years",{"count":116,"type":117},2000,"ESTIMATED","OBSERVATIONAL","The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary\u002Fprimary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania.",[121],"Pulmonary Disease, Chronic Obstructive","2026-06-15",{"date":124,"type":125},"2026-06-16","ACTUAL",{"date":127,"type":125},"2025-04-17",{"date":129,"type":117},"2026-12-14",{"name":5,"class":6},7]